BioCryst Pharma (BCRX) PT Raised to $23 at JMP Securities, Following Earnings
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $4.41 --0%
Rating Summary:
17 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 8 | New: 11
Rating Summary:
17 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 8 | New: 11
Join SI Premium – FREE
JMP Securities analyst Jonathan Wolleben raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $23.00 (from $22.00) while maintaining a Market Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UCB (UCB:BB) (UCBJY) PT Raised to EUR135 at UBS
- Morgan Stanley Double Downgrades AU Optronics (2409:TT) (AUO) to Underweight
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JMP Securities, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
